| 1.9 0.02 (1.06%) | 03-11 09:30 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
NanoVibronix, Inc., operating through its subsidiary NanoVibronix Ltd., develops and commercializes innovative, non-invasive devices that stimulate biological responses for therapeutic purposes. Their core focus areas include mitigating biofilm formation, accelerating wound repair, and alleviating pain. Key among their product line is UroShield, an ultrasound-based solution engineered to deter bacterial colonization and biofilm development in urinary catheters, thereby boosting antibiotic efficacy and reducing associated patient discomfort. They also offer PainShield and WoundShield, both patch-based therapeutic ultrasound technologies. PainShield targets relief from pain, muscle spasms, and joint contractures, while WoundShield is designed to foster tissue regeneration and promote healing in wounds. The company distributes these products directly to consumers and via extensive distributor networks spanning the United States, Israel, Europe, India, and numerous other international regions. Founded in 2003, NanoVibronix, Inc. maintains its corporate headquarters in Elmsford, New York.
Wed, 04 Jun 2025
NanoVibronix Appoints Doron Besser as CEO - citybiz
Wed, 23 Aug 2023
NanoVibronix Extends Distribution Agreement with Its Largest Distributor for PainShield and PainShield Plus - Business Wire
Wed, 22 Feb 2023
NanoVibronix to Launch Rental Program for PainShield and UroShield - BioSpace
Wed, 18 Jan 2023
NanoVibronix Provides Update on Expanding Access to PainShield - Business Wire
Mon, 30 May 2022
NanoVibronix Inc. (NAOV) Share Price Today | NanoVibronix (NAOV) Live NSE/BSE - valueresearchonline.com
Thu, 05 Aug 2021
NanoVibronix Applies for CMS Reimbursement Code for UroShield® and PainShield Plus® - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|